Zentalis Pharmaceuticals (ZNTL) News
NASDAQ: ZNTLHealth CareBiotechnology: Pharmaceutical PreparationsUSD
1.360.00 (0.00%)
At close: Nov 20, 4:00 PM ET · Delayed 15 min
ZNTL news summary
We found 6 recent headlines mentioning Zentalis Pharmaceuticals (ZNTL): 0 in the past week and 2 in the past 30 days, most often from GlobeNewswire, Nasdaq. For price context, ZNTL is up 0.00% at $1.36. The most recent story, "Zentalis Pharmaceuticals to Participate in Upcoming Investor Conferences", was published by GlobeNewswire on Nov 3, 2026.
Headlines link to the original publishers. MetaCap does not republish third-party articles.
Summary generated from market data by MetaCap's automated system. Methodology
Latest Zentalis Pharmaceuticals headlines
- Zentalis Pharmaceuticals to Participate in Upcoming Investor ConferencesSAN DIEGO, Nov. 03, 2026 (GLOBE NEWSWIRE) -- Zentalis ® Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical oncology innovator advancing late-stage development of investigational first-in-class WEE1…GlobeNewswire
- Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)SAN DIEGO, Nov. 02, 2026 (GLOBE NEWSWIRE) -- Zentalis ® Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical oncology innovator advancing late-stage development of investigational first-in-class WEE1…GlobeNewswire
- Zentalis Pharmaceuticals Announces Meaningful Median Overall Survival Data in Cyclin E1-Positive Platinum-Resistant Ovarian Cancer from DENALI Part 1b to be Presented at the ESMO Congress 2026SAN DIEGO, Oct. 23, 2026 (GLOBE NEWSWIRE) -- Zentalis ® Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical oncology innovator advancing late-stage development of investigational first-in-class WEE1…GlobeNewswire
- Zentalis Reports Interim OS Rates Of 15 Months In Cyclin-E1 PROC Patients Treated With Azenosertib(RTTNews) - Zentalis Pharmaceuticals Inc. (ZNTL), a clinical oncology company, on Sunday announced interim overall survival (OS) data from the Phase 2 DENALI Part 1b trial for azenosertib as a…NasdaqZNTL, DDS
- Zentalis Highlights Interim Survival Data From DENALI Part 1b Study Of Azenosertib In PROC(RTTNews) - Zentalis Pharmaceuticals, Inc. (ZNTL) announced that interim overall survival (OS) data from Part 1b of the Phase 2 DENALI (GOG-3066) trial evaluating azenosertib in platinum-resistant…NasdaqZNTL, ET
- Zentalis Pharmaceuticals Announces First Overall Survival Data for Azenosertib from DENALI Part 1b Published in ESMO Congress 2026 AbstractSAN DIEGO, Oct. 18, 2026 (GLOBE NEWSWIRE) -- Zentalis ® Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical oncology innovator advancing late-stage development of investigational first-in-class WEE1…GlobeNewswire